{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Advanced+or+Metastatic+KRAS-mutant+Tumor", "query": { "condition": "Advanced or Metastatic KRAS-mutant Tumor" }, "page_size": 10 }, "pagination": { "page": 1, "page_size": 10, "total_count": 22, "total_pages": 3, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Advanced+or+Metastatic+KRAS-mutant+Tumor&page=2&page_size=10", "previous_page_url": null }, "source": "remote", "last_synced_at": "2026-06-25T19:17:29.119Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT06119581", "title": "A Study of First-Line Olomorasib (LY3537982) and Pembrolizumab With or Without Chemotherapy in Patients With Advanced KRAS G12C-Mutant Non-small Cell Lung Cancer", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Carcinoma, Non-Small-Cell Lung", "Neoplasm Metastasis" ], "interventions": [ { "name": "LY3537982", "type": "DRUG" }, { "name": "Pembrolizumab", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" }, { "name": "Cisplatin", "type": "DRUG" }, { "name": "Carboplatin", "type": "DRUG" }, { "name": "Pemetrexed", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Eli Lilly and Company", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 1264, "start_date": "2023-12-21", "completion_date": "2031-01", "has_results": false, "last_update_posted_date": "2026-06-18", "last_synced_at": "2026-06-25T19:17:29.119Z", "location_count": 90, "location_summary": "Huntsville, Alabama • Gilbert, Arizona • Phoenix, Arizona + 74 more", "locations": [ { "city": "Huntsville", "state": "Alabama" }, { "city": "Gilbert", "state": "Arizona" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Tucson", "state": "Arizona" }, { "city": "Springdale", "state": "Arkansas" } ], "official_url": "https://clinicaltrials.gov/study/NCT06119581" }, { "nct_id": "NCT05638295", "title": "Testing the Use of AMG 510 (Sotorasib) and Panitumumab as a Targeted Treatment for KRAS G12C Mutant Solid Tumor Cancers (A ComboMATCH Treatment Trial)", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Advanced Malignant Solid Neoplasm", "Metastatic Malignant Solid Neoplasm" ], "interventions": [ { "name": "Biopsy Procedure", "type": "PROCEDURE" }, { "name": "Biospecimen Collection", "type": "PROCEDURE" }, { "name": "Computed Tomography", "type": "PROCEDURE" }, { "name": "Magnetic Resonance Imaging", "type": "PROCEDURE" }, { "name": "Panitumumab", "type": "BIOLOGICAL" }, { "name": "Sotorasib", "type": "DRUG" } ], "intervention_types": [ "PROCEDURE", "BIOLOGICAL", "DRUG" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 105, "start_date": "2024-08-01", "completion_date": "2028-12-31", "has_results": false, "last_update_posted_date": "2026-05-13", "last_synced_at": "2026-06-25T19:17:29.119Z", "location_count": 180, "location_summary": "Birmingham, Alabama • Mobile, Alabama • Los Angeles, California + 135 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Mobile", "state": "Alabama" }, { "city": "Los Angeles", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Palo Alto", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT05638295" }, { "nct_id": "NCT05132075", "title": "Study of JDQ443 in Comparison With Docetaxel in Participants With Locally Advanced or Metastatic KRAS G12C Mutant Non-small Cell Lung Cancer", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Non-Small Cell Lung Cancer" ], "interventions": [ { "name": "JDQ443", "type": "DRUG" }, { "name": "docetaxel", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Novartis Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "100 Years", "sex": "ALL", "summary": "18 Years to 100 Years" }, "enrollment_count": 95, "start_date": "2022-06-15", "completion_date": "2026-09-23", "has_results": false, "last_update_posted_date": "2026-06-25", "last_synced_at": "2026-06-25T19:17:29.119Z", "location_count": 1, "location_summary": "Renton, Washington", "locations": [ { "city": "Renton", "state": "Washington" } ], "official_url": "https://clinicaltrials.gov/study/NCT05132075" }, { "nct_id": "NCT07190248", "title": "A Clinical Study of Calderasib (MK-1084) and Other Treatments for Participants With Non-Small Cell Lung Cancer (MK-1084-007/KANDLELIT-007)", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Non-small Cell Lung Cancer" ], "interventions": [ { "name": "Calderasib", "type": "DRUG" }, { "name": "Pembrolizumab (+) Berahyaluronidase alfa", "type": "BIOLOGICAL" }, { "name": "Pemetrexed", "type": "DRUG" }, { "name": "Cisplatin", "type": "DRUG" }, { "name": "Carboplatin", "type": "DRUG" } ], "intervention_types": [ "DRUG", "BIOLOGICAL" ], "sponsor": "Merck Sharp & Dohme LLC", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 675, "start_date": "2025-10-08", "completion_date": "2032-08-06", "has_results": false, "last_update_posted_date": "2026-06-12", "last_synced_at": "2026-06-25T19:17:29.119Z", "location_count": 9, "location_summary": "Birmingham, Alabama • Stamford, Connecticut • Miami Beach, Florida + 6 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Stamford", "state": "Connecticut" }, { "city": "Miami Beach", "state": "Florida" }, { "city": "Lafayette", "state": "Indiana" }, { "city": "Westbrook", "state": "Maine" } ], "official_url": "https://clinicaltrials.gov/study/NCT07190248" }, { "nct_id": "NCT03948763", "title": "A Study of mRNA-5671/V941 as Monotherapy and in Combination With Pembrolizumab (V941-001)", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Neoplasms", "Carcinoma, Non-Small-Cell Lung", "Pancreatic Neoplasms", "Colorectal Neoplasms" ], "interventions": [ { "name": "V941", "type": "BIOLOGICAL" }, { "name": "Pembrolizumab", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "Merck Sharp & Dohme LLC", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 70, "start_date": "2019-06-26", "completion_date": "2022-08-25", "has_results": true, "last_update_posted_date": "2025-01-28", "last_synced_at": "2026-06-25T19:17:29.119Z", "location_count": 10, "location_summary": "Gilbert, Arizona • Duarte, California • San Francisco, California + 7 more", "locations": [ { "city": "Gilbert", "state": "Arizona" }, { "city": "Duarte", "state": "California" }, { "city": "San Francisco", "state": "California" }, { "city": "New Haven", "state": "Connecticut" }, { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT03948763" }, { "nct_id": "NCT07639242", "title": "Olomorasib + Pembrolizumab KRAS G12C Mutant, PD-L1 TPS 1-49% Locally Advanced or Metastatic NSCLC", "overall_status": "NOT_YET_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Lung Cancer", "Lung Cancer (NSCLC)", "Locally Advanced NSCLC", "Metastatic NSCLC - Non-Small Cell Lung Cancer" ], "interventions": [ { "name": "Olomorasib", "type": "DRUG" }, { "name": "Pembrolizumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "UNC Lineberger Comprehensive Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 60, "start_date": "2026-06", "completion_date": "2030-06-21", "has_results": false, "last_update_posted_date": "2026-06-10", "last_synced_at": "2026-06-25T19:17:29.119Z", "location_count": 1, "location_summary": "Chapel Hill, North Carolina", "locations": [ { "city": "Chapel Hill", "state": "North Carolina" } ], "official_url": "https://clinicaltrials.gov/study/NCT07639242" }, { "nct_id": "NCT06208124", "title": "A Study of IMM-6-415 in RAS/RAF Mutant Solid Tumors", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Advanced Solid Tumor (Phase 1)", "Pancreas Adenocarcinoma", "Non-small Cell Lung Cancer", "Malignant Melanoma (Cutaneous)" ], "interventions": [ { "name": "IMM-6-415", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Immuneering Corporation", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 30, "start_date": "2024-02-27", "completion_date": "2025-04-30", "has_results": false, "last_update_posted_date": "2025-05-28", "last_synced_at": "2026-06-25T19:17:29.119Z", "location_count": 5, "location_summary": "Scottsdale, Arizona • Duarte, California • Denver, Colorado + 2 more", "locations": [ { "city": "Scottsdale", "state": "Arizona" }, { "city": "Duarte", "state": "California" }, { "city": "Denver", "state": "Colorado" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT06208124" }, { "nct_id": "NCT02974725", "title": "A Phase Ib Study of LXH254-centric Combinations in NSCLC or Melanoma", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Non-Small Cell Lung Cancer", "Melanoma" ], "interventions": [ { "name": "LXH254", "type": "DRUG" }, { "name": "LTT462", "type": "DRUG" }, { "name": "Trametinib", "type": "DRUG" }, { "name": "Ribociclib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Novartis Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 241, "start_date": "2017-02-24", "completion_date": "2024-04-24", "has_results": false, "last_update_posted_date": "2025-04-13", "last_synced_at": "2026-06-25T19:17:29.119Z", "location_count": 6, "location_summary": "San Diego, California • San Francisco, California • Boston, Massachusetts + 3 more", "locations": [ { "city": "San Diego", "state": "California" }, { "city": "San Francisco", "state": "California" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "New York", "state": "New York" }, { "city": "Nashville", "state": "Tennessee" } ], "official_url": "https://clinicaltrials.gov/study/NCT02974725" }, { "nct_id": "NCT05180422", "title": "A Phase I/II Study of AMG 510 in Combination With MVASI in Patients With Advanced, Unresectable or Metastatic KRAS G12C Mutant NSCLC With Asymptomatic Brain Metastasis", "overall_status": "WITHDRAWN", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Non Small Cell Lung Cancer" ], "interventions": [ { "name": "AMG 510", "type": "DRUG" }, { "name": "MVASI", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Criterium, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 0, "start_date": "2022-06-15", "completion_date": "2023-01-31", "has_results": false, "last_update_posted_date": "2023-10-18", "last_synced_at": "2026-06-25T19:17:29.119Z", "location_count": 1, "location_summary": "Nashville, Tennessee", "locations": [ { "city": "Nashville", "state": "Tennessee" } ], "official_url": "https://clinicaltrials.gov/study/NCT05180422" }, { "nct_id": "NCT01986166", "title": "A Study of MEHD7945A and Cobimetinib in Patients With Locally Advanced or Metastatic Cancers With Mutant KRAS", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Neoplasms" ], "interventions": [ { "name": "Cobimetinib", "type": "DRUG" }, { "name": "MEHD7945A", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Genentech, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 23, "start_date": "2013-11", "completion_date": "2016-01", "has_results": false, "last_update_posted_date": "2016-07-18", "last_synced_at": "2026-06-25T19:17:29.119Z", "location_count": 6, "location_summary": "San Francisco, California • Denver, Colorado • New Haven, Connecticut + 3 more", "locations": [ { "city": "San Francisco", "state": "California" }, { "city": "Denver", "state": "Colorado" }, { "city": "New Haven", "state": "Connecticut" }, { "city": "Detroit", "state": "Michigan" }, { "city": "Nashville", "state": "Tennessee" } ], "official_url": "https://clinicaltrials.gov/study/NCT01986166" } ] }